We believe that the expression level of tumor tissue or serum HMGB1 combined with the PB CD62Ldim neutrophil percentage may be a prospective strategy to predict the possibility of tumor metastasis in breast cancer patients. This evidence concerns the gene HMGB1 and breast cancer.